Page 92 - 《中国药房》2023年8期
P. 92
依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗
效、安全性和经济性
Δ
1 #
2
1＊
李 龙 ，王 彬 ，曲 政 ，黄俊荣（1.牡丹江医学院附属第二医院药剂科，黑龙江 牡丹江 157011；2.牡丹
2
江医学院药学院，黑龙江 牡丹江 157011）
中图分类号 R956；R544.1 文献标志码 A 文章编号 1001-0408（2023）08-0978-05
DOI 10.6039/j.issn.1001-0408.2023.08.16
摘 要 目的 评价依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性，为临床治疗选择提供决
策参考。方法 收集2021年1月－2021年12月住院治疗的488例急性缺血性脑卒中患者的病历资料，根据治疗方案分为两组，其
中依达拉奉右莰醇组268例，复方脑肽节苷脂组220例。应用倾向性评分匹配法平衡两组基线水平后，依据治疗前后美国国立卫
生研究院卒中量表（NIHSS）评分的变化情况评定疗效；从医院不良反应上报系统中收集患者的不良反应发生情况；从中国卫生体
系角度出发，分析两种方案的经济性，并进行单因素敏感性分析。结果 倾向性评分匹配后，依达拉奉右莰醇组和复方脑肽节苷脂
组各纳入患者125例，有效率分别为81.6%和74.4%，疗效无显著性差异，成本平均值分别为13 560.30元和14 958.68元，依达拉奉
右莰醇组的成本更低。两组均未检索到不良反应上报信息。单因素敏感性分析结果显示，复方脑肽节苷脂组的其他药品费为较
为敏感的参数。结论 依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的短期疗效和安全性相当，但依达拉奉右莰醇方
案的成本更低，是更为经济的方案。
关键词 依达拉奉右莰醇；复方脑肽节苷脂；神经保护剂；缺血性脑卒中；有效性；安全性；经济性；最小成本分析
Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside
ganglioside in the treatment of acute ischemic stroke
LI Long ，WANG Bin ，QU Zheng ，HUANG Junrong（1. Dept. of Pharmacy， the Second Affiliated Hospital of
2
2
1
1
Mudanjiang Medical University， Heilongjiang Mudanjing 157011， China；2. College of Pharmacy， Mudanjiang
Medical University， Heilongjiang Mudanjing 157011， China）
ABSTRACT OBJECTIVE To evaluate efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine
cerebroside ganglioside in the treatment of acute ischemic stroke， and to provide decision-making reference for clinical treatment
selection. METHODS The medical records of 488 patients with acute ischemic stroke hospitalized from Jan. 2021 to Dec. 2021
were collected and divided into two groups according to the treatment plan， i.e. 268 patients in edaravone dexborneol group， and
220 patients in compound porcine cerebroside ganglioside group. After baseline levels of the two groups were balanced using
propensity score matching method， curative effect was evaluated according to the changes of NIHSS scores before and after
treatment； the occurrence of adverse drug reactions in patients were collected from the hospital adverse reaction reporting system；
from the perspective of China’s health system， the cost-effectiveness of the two options were analyzed， and one-way sensitivity
analysis was conducted. RESULTS After the propensity score matching， 125 patients were included in the edaravone dexborneol
group and compound porcine cerebroside ganglioside group， respectively. The response rates were 81.6% and 74.4%， respectively，
with no significant difference. The average costs were 13 560.30 yuan and 14 958.68 yuan， respectively； the cost of edaravone
dexborneol group was lower than that of compound porcine cerebroside ganglioside group. No adverse reaction reporting information
was retrieved in both groups. Results of one-way sensitivity analysis showed that other drug costs in compound porcine cerebroside
ganglioside group was relatively sensitive parameters. CONCLUSIONS Short-term efficacy and safety of edaravone dexborneol are
equivalent to those of compound porcine cerebroside ganglioside in treating acute ischemic stroke. But edaravone dexborneol
regimen had lower cost and is a more economical scheme.
KEYWORDS edaravone dexborneol； compound porcine cerebroside ganglioside； neuroprotective agent； ischemic stroke； efficacy；
safety； cost-effectiveness； cost-minimization analysis
Δ 基金项目 牡 丹 江 医 学 院 研 究 生 导 师 科 研 专 项 计 划（No.
YJSZX2022161）
＊第一作者 硕士研究生。研究方向：临床合理用药方案制定、不 随着人口老龄化以及一些危险因素的积累，脑卒中
良反应监测、药物经济学。E-mail：1978595183@qq.com
发病率近年来呈现井喷式增长，已经成为全球第二大死
# 通信作者 主任药师，硕士生导师，硕士。研究方向：临床合理用
[1]
药方案制定、不良反应监测、药物经济学。E-mail：455393595@qq.com 亡原因，被认为是导致长期残疾的重要原因之一 。在
· 978 · China Pharmacy 2023 Vol. 34 No. 8 中国药房 2023年第34卷第8期
